Last updated: 2026-09-24 13:55:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Spyre Therapeutics, Inc. (SYRE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $85.70, with a market capitalization of $8.11B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15.49 to $110.18. This page covers its latest market performance, valuation, price trends and company information.
$8.11B | |
$87.46 | |
$110.18 | |
$10.42 | |
$88.17 | |
45.58K | |
1.21M | |
-- | |
$110.18 | |
$15.49 | |
-- | |
-- |
Spyre Therapeutics, Inc. (SYRE) is currently trading at $85.70 as of 2026-09-24 13:53:00, down 2.81% ($2.48) from the previous close of $88.17
During today's regular trading session, SYRE has traded between $10.42 and $110.18, with a trading volume of 45.58K shares. The current price is near the upper end of today's range.
Over the past seven days, Spyre Therapeutics, Inc. (SYRE) moved from $90.95 to $85.70, representing a decline of 5.78% ($5.26).
The stock traded between $85.64 and $95.19 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.50 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 74.1%
SYRE is currently trading at $85.70, placing it 74.1% of the way from its 52-week low of $15.49 to its 52-week high of $110.18. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 112 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Spyre Therapeutics, Inc. (SYRE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.